Shareholders are investing 8.3 million Euro in the expanding business–Rainer Hepberger new CFO–Phase III study begins for ICES13

B3C newswire, 04/27/2012

In order to continue on its agreed expansion course, the Austrian biotechnology company Innovacell is acquiring fresh capital: shareholders in the firm, which is developing cell–therapy for the treatment of stress–urinary incontinence (ICES13) and faecal incontinence, have agreed on a capital expansion of 8.3 million Euro. This will take effect in two tranches. The main shareholders are the financial investors Buschier, Fides, HYBAG und the private equity firm, uni venture.

Print Article Summary Cat 2 CME Report